OBJECTIVES: To assess the impact of highly active antiretroviral therapy (HAART) on the onset of first disseminated Mycobacterium avium complex (MAC) infection and first cytomegalovirus (CMV) disease episode in HIV-infected at-risk patients. METHODS: The incidence of the two infections occurring in at-risk patients was calculated for two periods (January 1995-June 1996 and July 1996-December 1997) using the database of the HIV-infected patients followed in the Infectious Diseases Department at the Pitié-Salpêtrière Hospital in Paris. HAART was progressively introduced in late June 1996 in France. RESULTS: A total of 91 first disseminated MAC infections and 124 first CMV disease episodes were recorded. The incidence of first disseminated MAC infections fell from 13.4 per 100 person-years in the first 18-month period to 2.6 per 100 person-years in the second 18-month period. Similarly, the incidence of first CMV disease episodes fell from 20.9 to 3.5 per 100 person-years. Fourteen patients on HAART developed a first MAC infection, 12 (85.7%) within 2 months of starting HAART. Nineteen patients on HAART had a first CMV disease episode, 10 (52.6%) within 2 months of starting HAART. CONCLUSIONS: HAART led to a five-fold decrease in the incidence of first disseminated MAC infections and a six-fold decrease in first CMV disease episodes, although patients remain vulnerable to both diseases for approximately 2 months after starting HAART.
OBJECTIVES: To assess the impact of highly active antiretroviral therapy (HAART) on the onset of first disseminated Mycobacterium avium complex (MAC) infection and first cytomegalovirus (CMV) disease episode in HIV-infected at-risk patients. METHODS: The incidence of the two infections occurring in at-risk patients was calculated for two periods (January 1995-June 1996 and July 1996-December 1997) using the database of the HIV-infectedpatients followed in the Infectious Diseases Department at the Pitié-Salpêtrière Hospital in Paris. HAART was progressively introduced in late June 1996 in France. RESULTS: A total of 91 first disseminated MACinfections and 124 first CMV disease episodes were recorded. The incidence of first disseminated MACinfections fell from 13.4 per 100 person-years in the first 18-month period to 2.6 per 100 person-years in the second 18-month period. Similarly, the incidence of first CMV disease episodes fell from 20.9 to 3.5 per 100 person-years. Fourteen patients on HAART developed a first MACinfection, 12 (85.7%) within 2 months of starting HAART. Nineteen patients on HAART had a first CMV disease episode, 10 (52.6%) within 2 months of starting HAART. CONCLUSIONS: HAART led to a five-fold decrease in the incidence of first disseminated MACinfections and a six-fold decrease in first CMV disease episodes, although patients remain vulnerable to both diseases for approximately 2 months after starting HAART.
Authors: John A Crump; David C Tanner; Stanley Mirrett; Celeste M McKnight; L Barth Reller Journal: J Clin Microbiol Date: 2003-05 Impact factor: 5.948
Authors: I Yust; Z Fox; M Burke; A Johnson; D Turner; A Mocroft; C Katlama; B Ledergerber; P Reiss; O Kirk Journal: Eur J Clin Microbiol Infect Dis Date: 2004-06-30 Impact factor: 3.267
Authors: John H Kempen; Elizabeth A Sugar; Rohit Varma; James P Dunn; Murk-Hein Heinemann; Douglas A Jabs; Alice T Lyon; Richard A Lewis Journal: Ophthalmology Date: 2014-08-08 Impact factor: 12.079
Authors: V Martinez; E Caumes; L Gambotti; H Ittah; J-P Morini; J Deleuze; I Gorin; C Katlama; F Bricaire; N Dupin Journal: Br J Cancer Date: 2006-04-10 Impact factor: 7.640
Authors: Maha A Al-Mozaini; Michael K Mansour; Abdullah A Al-Hokail; Magid A Mohmed; Munirah A Bin Daham; Hail M Al-Abdely; Husn H Frayha; Fahad A Al-Rabiah; Sami H Alhajjar; Salmaan Keshavjee; Chaker N Adra; Abdulrahman A Alrajhi Journal: J AIDS Clin Res Date: 2014-11-08